Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017093147) METHOD FOR INACTIVATING XENOANTIGENS IN BIOLOGICAL TISSUES
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

CLAIMS

1. A method for inactivating xenoantigens in biological tissues, particularly in tissues that can be used to manufacture bioprosthetic substitutes and/or in bioprosthetic substitutes that are already prepared and intended for human or veterinary clinical use, characterized in that it entails the following steps:

- providing a solution based on phenolic compounds, polyphenolic compounds or derivatives thereof, for the inactivation of at least part of the xenogeneic epitopes from said tissues;

- incubating the samples to be treated in the various solutions based on phenols/polyphenols in controlled conditions;

- subjecting the treated tissues to a series of washes.

2. The method according to claim 1, characterized in that said biological tissues are constituted by native, or native and fixed, or fixed connective tissues.

3. The method according to one or more of the preceding claims, characterized in that said biological tissues are heterologous or homologous.

4. The method according to one or more of the preceding claims, characterized in that said antigenic epitope is the alpha-Gal antigen.

5. The method according to one or more of the preceding claims, characterized in that said controlled conditions comprise at least treatment at the temperature of 40±2°C.

6. The method according to one or more of the preceding claims, characterized in that said phenolic compounds, polyphenolic compounds or derivatives thereof for the inactivation of at least part of said xenogeneic epitopes from said tissues are constituted by derivatives of cinnamic acid, tannin and oleuropein.

7. The method according to claim 6, characterized in that said derivatives of cinnamic acid are constituted by caffeic acid.

8. The method according to claim 6, characterized in that said tannin derivatives are constituted by tannic acid.

9. The method according to claim 6, characterized in that said oleuropein derivatives are constituted by hydroxytyrosol.

10. The method according to one or more of the preceding claims, characterized in that at least one phenyl derivative of cinnamic acid is constituted by caffeic acid.

11. The method according to one or more of the preceding claims, characterized in that at least one phenyl derivative of tannin is constituted by tannic acid.

12. The method according to one or more of the preceding claims, characterized in that at least one phenyl derivative of oleuropein is constituted by hydroxytyrosol.

13. Connective tissue obtained with a method according to one or more of the preceding claims, characterized in that it has at least part of the antigen component in inactive form.

14. Use of connective tissue according to one or more of the preceding claims for the manufacture of bioprosthetic substitutes and/or parts of bioprosthetic substitutes that are already prepared, for use in the human or veterinary clinical field.

15. A kit for carrying out a method for inactivating xenoantigens in biological tissues according to one or more of the preceding claims, characterized in that it comprises at least:

- one or more containers containing the buffer in which the most suitable dose of phenolic compounds, polyphenolic compounds or derivatives thereof is to be dissolved;

- one or more containers containing the dose of phenolic compounds, polyphenolic compounds or derivatives thereof in powder form to be combined with the buffer;

- one or more containers containing the washing buffers;

- an instruction booklet containing the description of the timings and modes of application of the procedure.